Human milk oligosaccharides and application thereof in preparation of medicines for treating or preventing NEC by relieving intestinal tract hypoxia injury

A technology for human milk oligosaccharides and uses, applied in the preparation of sugar derivatives, dairy products, sugar derivatives, etc., can solve the problems of low content and structure complexity, unclear mechanism of action, and limited wide application, etc. Apoptosis, preventing morbidity, reducing the effect of cellular inflammatory response

Inactive Publication Date: 2019-11-22
CHINA AGRI UNIV
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, only two kinds of HMOs are allowed to be added to infant formula milk powder, and the rest are replaced by galacto-oligosaccharides and fructo-oligosaccharides, which are far lower than the actual situation in human milk in terms of content and structure complexity, but the current HMOs There are still many controversies in physiological functions, and its mechanism of action is still unclear
Therefore, its wide application is limited

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Human milk oligosaccharides and application thereof in preparation of medicines for treating or preventing NEC by relieving intestinal tract hypoxia injury
  • Human milk oligosaccharides and application thereof in preparation of medicines for treating or preventing NEC by relieving intestinal tract hypoxia injury
  • Human milk oligosaccharides and application thereof in preparation of medicines for treating or preventing NEC by relieving intestinal tract hypoxia injury

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0030] This embodiment provides a kind of human milk oligosaccharide, the preparation method of described human milk oligosaccharide is:

[0031] Mix 10L of human milk evenly, and centrifuge at 14000g for 30min at 4°C to remove fat. The collected whey is ultrafiltered with a 10kd ultrafiltration membrane to remove protein and residual fat. The filtrate was treated with 2 volumes of absolute ethanol, and precipitated overnight at 4°C. After centrifuging at 12000g to remove the precipitate, the finally collected supernatant was freeze-dried to obtain crude oligosaccharides. Crude oligosaccharides were separated by Luna HILIC column (10×250mm, 5μm, Phenomenex) to remove lactose, chromatographic conditions: A liquid ultrapure water, B liquid chromatography pure acetonitrile, 0–40min, 80%–50%B; 40–45min , 20% B; 45–55min, 80% B. One tube of filtrate was recovered every minute, and the filtrate was identified by HPLC-MS / MS-QTOF (Agilent 6545, USA). , Phenomenex), the chromatograp...

Embodiment 2

[0076] This embodiment provides an infant formula milk powder added with human milk oligosaccharides, its formula is: protein 10g / 100g, fat 28g / 100g, carbohydrate 52g / 100g, taurine 34mg / 100g, L-carnitine 7.5mg / 100g, inositol 32mg / 100g, β-carotene 61mg / 100g, lutein 100μg / 100g, calcium 380mg / 100g, phosphorus 224mg / 100g, magnesium 40mg / 100g, sodium 144mg / 100g, potassium 625mg / 100g, chlorine 350mg / 100g, Zinc 4.5mg / 100g, Iron 5.4mg / 100g, Copper 400μg / 100g, Manganese 100μg / 100g, Iodine 100μg / 100g, Selenium 12.3μg / 100g, Vitamin A190 IU / 100g, Vitamin D 380 IU / 100g, International Units of Vitamin E / 100g, Vitamin K 1 54μg / 100g, vitamin C 80mg / 100g, vitamin B 1 660μg / 100g, Vitamin B 2 1100μg / 100g, Vitamin B 6 400μg / 100g, Vitamin B 12 1.5μg / 100g, niacin 5000μg / 100g, pantothenic acid 2600μg / 100g, folic acid 76μg / 100g, biotin 20μg / 100g, choline 80mg / 100g, nucleotide 58mg / 100g, energy 510kcal / 100g. The human milk oligosaccharides used are the human milk oligosaccharides prepared b...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
concentrationaaaaaaaaaa
Login to view more

Abstract

The invention discloses human milk oligosaccharides and application thereof in preparation of medicines for treating or preventing NEC by relieving intestinal tract hypoxia injury. Human milk is subjected to centrifugation to remove fat to obtain whey; the whey is subjected to ultrafiltration and ethanol treatment to obtain crude oligosaccharides; the crude oligosaccharides are subjected to chromatography and mass spectrometry treatment to remove lactose-containing components; and freeze-drying is performed to obtain the purified human milk oligosaccharides (HMOs). The composition of the obtained purified human milk oligosaccharides (HMOs) is similar to that of HMOs in natural human milk. A large number of animal experiments prove that the obtained purified HMOs can effectively relieve intestinal tract hypoxia injury, in manners of promoting intestinal epithelial cell proliferation, resisting cell apoptosis and reducing cell inflammatory response, so that necrotizing enterocolitis is treated or the morbidity of necrotizing enterocolitis is reduced.

Description

technical field [0001] The invention belongs to the field of food biotechnology, and in particular relates to a human milk oligosaccharide and its use in the preparation of medicines for treating or preventing NEC by alleviating intestinal hypoxic damage. Background technique [0002] Necrotizing enterocolitis (Necrotizing enterocolitis, NEC) is a common disease in premature infants with high fatality rate, the fatality rate is between 10% and 50%. At present, the treatment methods for NEC are very limited. In the early stage, antibiotic therapy is usually used for relief, and in the late stage, surgery can only be used for treatment. However, postoperative complications of the nervous system and digestive system are often accompanied, which seriously affect the growth and development of the baby. Therefore, prevention against the possible risks of NEC is an ideal means of prevention and control. [0003] According to current research, there are two major pathogenesis mecha...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C08B37/00C07H1/08C07H3/04C07H3/06A61K31/7016A61K31/702A61K31/715A61P1/00A23L33/125A23C9/13A23C9/156
CPCA23C9/1307A23C9/156A23L33/125A23V2002/00A61K31/715A61P1/00C07H1/08C07H3/04C07H3/06C08B37/003A23V2200/32A23V2250/612
Inventor 任发政王辰元李一然王然
Owner CHINA AGRI UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap